Alpha 2.0
Login Register
» Authors » Ahmed Elkamhawy

Ahmed Elkamhawy

Explore the profile of Ahmed Elkamhawy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 475
Followers 0
Related Specialties
Chemistry
Biochemistry
Biology
Top 10 Co-Authors
Eun Joo Roh
Kyeong Lee
Ae Nim Pae
Sora Paik
Hossam Nada
Ahmed H E Hassan
Ahmed A Al-Karmalawy
Magda H Abdellattif
Jung-Eun Park
Mohamed H Elsherbeny
Published In
Eur J Med Chem
J Enzyme Inhib Med Chem
Pharmaceuticals (Basel)
Bioorg Chem
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening
Elkamhawy A, Ammar U, Kim M, Gul A, Park T, Lee K
Arch Pharm Res . 2025 Feb; 48(2):150-165. PMID: 39920399
Raf kinase enzymes are often dysregulated in melanoma. While sorafenib demonstrates strong activity against wild-type B-Raf, it fails to effectively inhibit the mutated form of B-Raf. In this study, sorafenib...
2.
Pyrimidine scaffold dual-target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure-activity relationship (2018‒2023)
Song M, Elkamhawy A, Noh W, Abdelazem A, Park Y, Sivaraman A, et al.
Arch Pharm (Weinheim) . 2025 Jan; 358(1):e2400163. PMID: 39828961
Cancer, the second leading cause of death globally, causes a significant threat to life. Despite advancements in the treatment of cancer, persistent challenges include severe side effects and the emergence...
3.
Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets
Lee H, Elkamhawy A, Rakhalskaya P, Lu Q, Nada H, Quan G, et al.
Pharmaceuticals (Basel) . 2025 Jan; 17(12. PMID: 39770531
Parkinson's disease (PD) is a chronic, progressive neurological disorder affecting approximately 10 million people worldwide, with prevalence expected to rise as the global population ages. It is characterized by the...
4.
Chalcone-based benzenesulfonamides as potent and selective inhibitors for human carbonic anhydrase II: Design, synthesis, in vitro, and in silico studies
Lee H, Elkamhawy A, Al-Karmalawy A, Nada H, Giovannuzzi S, Supuran C, et al.
Arch Pharm (Weinheim) . 2024 Sep; 357(11):e2400069. PMID: 39240035
Sulfonamides are promising classical carbonic anhydrase (CA; EC 4.2.1.1) inhibitors, being used for several medical purposes such as diuretics, anticonvulsants, topically acting antiglaucoma agents, for antiobesity and anticancer therapies. Herein,...
5.
Rational design, synthesis, biological evaluation, and molecular modeling of novel naphthamide derivatives possessing potent, reversible, and competitive inhibitory mode of action over human monoamine oxidase
Elkamhawy A, Oh J, Kim M, El-Halaby L, Abdellattif M, Al-Karmalawy A, et al.
Mol Divers . 2024 May; 29(1):179-193. PMID: 38727994
Herein, a novel series of naphthamide derivatives has been rationally developed, synthesized, and evaluated for their inhibitory activity against monoamine oxidase (MAO) and cholinesterase (ChE) enzymes. Compared to the reported...
6.
Correction: Elsherbeny et al. 2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation. 2022, , 876
Elsherbeny M, Ammar U, Abdellattif M, Abourehab M, Abdeen A, Ibrahim S, et al.
Life (Basel) . 2024 Apr; 14(4). PMID: 38672808
In the original publication [...].
7.
Therapeutic potential of natural products in inflammation: underlying molecular mechanisms, clinical outcomes, technological advances, and future perspectives
Gouda N, Alshammari S, Abourehab M, Alshammari Q, Elkamhawy A
Inflammopharmacology . 2023 Nov; 31(6):2857-2883. PMID: 37950803
Chronic inflammation is a common underlying factor in many major diseases, including heart disease, diabetes, cancer, and autoimmune disorders, and is responsible for up to 60% of all deaths worldwide....
8.
Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments
Antar S, Ashour N, Sharaky M, Khattab M, Ashour N, Zaid R, et al.
Biomed Pharmacother . 2023 Oct; 168:115734. PMID: 37857245
Nowadays, diabetes mellitus has emerged as a significant global public health concern with a remarkable increase in its prevalence. This review article focuses on the definition of diabetes mellitus and...
9.
Machine Learning-Based Approach to Developing Potent EGFR Inhibitors for Breast Cancer-Design, Synthesis, and In Vitro Evaluation
Nada H, Gul A, Elkamhawy A, Kim S, Kim M, Choi Y, et al.
ACS Omega . 2023 Sep; 8(35):31784-31800. PMID: 37692247
The epidermal growth factor receptor (EGFR) is vital for regulating cellular functions, including cell division, migration, survival, apoptosis, angiogenesis, and cancer. EGFR overexpression is an ideal target for anticancer drug...
10.
Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers
El-Kalyoubi S, Khalifa M, Abo-Elfadl M, El-Sayed A, Elkamhawy A, Lee K, et al.
J Enzyme Inhib Med Chem . 2023 Aug; 38(1):2242714. PMID: 37592917
A new wave of dual Topo I/II inhibitors was designed and synthesised via the hybridisation of spirooxindoles and pyrimidines. selenium nanoparticles (SeNPs) for some derivatives were synthesised. The targets and...